Aandelen in “Productie van analytische laboratoriuminstrumenten”

Aandeel Datum Koers Evolutie
vlag EyePoint Pharmaceuticals Inc 1/07 9,550 USD
+1,49% 		+1,49%

Nieuws over “Productie van analytische laboratoriuminstrumenten”

14/05 · Illumina To Webcast Upcoming Investor Conference · Persbericht

14/05 · Illumina To Webcast Upcoming Investor Conference · Persbericht

14/05 · Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-Derived Extracellular Vesicles from Plasma · Persbericht

13/05 · Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications · Persbericht

8/05 · Illumina Reports Financial Results for First Quarter of Fiscal Year 2025 · Persbericht

8/05 · Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets · Persbericht

6/05 · Waters Integrates Multi-Angle Light Scattering Detectors with Empower Software for Improved Biologics Quality Control and Simplified Regulatory Compliance · Persbericht

6/05 · Waters Corporation (NYSE: WAT) Reports First Quarter 2025 Financial Results · Persbericht

2/05 · Avantor® to Participate in Bank of America Securities 2025 Health Care Conference · Persbericht

1/05 · Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development · Persbericht

25/04 · Avantor® Announces CEO Transition · Persbericht

25/04 · Avantor® Reports First Quarter 2025 Results · Persbericht

15/04 · Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation · Persbericht

10/04 · Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025 · Persbericht

8/04 · Waters Corporation Schedules First Quarter 2025 Earnings Conference Call · Persbericht

1/04 · Avantor® Showcases Scalable Fluid Handling Innovations at INTERPHEX · Persbericht

1/04 · Waters Expands Alliance iS Bio HPLC Product Line with Photodiode Array Detector to Enhance Spectral Insights for Biopharma Development & QC · Persbericht

Mijn selecties